Get the Stockscreener App
7.16
1.56%
0.11
After Hours:
7.16
Aura Biosciences Inc stock is traded at $7.16, with a volume of 252.13K.
It is up +1.56% in the last 24 hours and up +2.29% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$7.05
Open:
$7.1
24h Volume:
252.13K
Relative Volume:
0.40
Market Cap:
$740.60M
Revenue:
-
Net Income/Loss:
$-112.39M
P/E Ratio:
-4.0606
EPS:
-1.7633
Net Cash Flow:
$-91.64M
1W Performance:
+4.99%
1M Performance:
+2.29%
6M Performance:
+26.50%
1Y Performance:
-0.97%
1-Day Range:
$7.05
$7.31
1-Week Range:
$6.71
$7.31
52-Week Range:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.16 | 729.23M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing - Stock Titan
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AURA|Aura Biosciences Inc|Price:7.050|Chg%:-0.150 - TradingKey
TradingKey - TradingKey
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aura Biosciences, Inc. Revenue Breakdown – BOATS:AURA - TradingView
Aura Biosciences Reaffirmed at Buy with Unchanged $23 Target on Bel-sar’s Vision-Sparing Potential - TipRanks
The Technical Signals Behind (AURA) That Institutions Follow - Stock Traders Daily
Price to earnings forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Price to book forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Enterprise value to revenue forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Enterprise value to EBITDA forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Price to sales forward of Aura Biosciences, Inc. – NASDAQ:AURA - TradingView
Form 4 Aura Biosciences Inc For: 8 July By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant - Stock Titan
Aura Biosciences (NASDAQ: AURA) files initial Form 3 for director Jeremy Bender - Stock Titan
Aura Biosciences Announces Appointment of Jer - Moomoo
Aura Biosciences strengthens board with new independent director - TipRanks
Aura Biosciences Appoints Jeremy Bender to Board as Bel-Sar Advances Toward Potential Regulatory Approval for Choroidal Melanoma 1 – Minichart - Minichart
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors - The Manila Times
Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director - Stock Titan
Aura Biosciences appoints Jeremy Bender to Boar... - Pluang
Aura Biosciences Insiders Made A Wise Decision By Selling US$939k Worth Of Stock - 富途牛牛
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Stock Climbs on Pipeline ProgressSpecial Dividend Alert - dars.gov.et
More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k - simplywall.st
Executive at Aura Biosciences (AURA) receives 14,858 RSUs - Stock Titan
Aura Biosciences, Inc. ($AURA) Former President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
AURA | Aura Biosciences, Inc. Common Executive Compensation - Quiver Quantitative
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com - Investing.com Nigeria
Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak - Stock Titan
Aura Biosciences Inc Actuals & Estimates (BOATS:AURA) - TradingView
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA) - TradingView
AURA Forecast — Price Target — Prediction for 2027 - TradingView
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones - Stock Traders Daily
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aura Biosciences Inc (AURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Inc (AURA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak - Stock Titan
Top Aura Biosciences Executive Quietly Unloads Shares in Notable Insider Move - TipRanks
Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares - Stock Titan
Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding - Stock Titan
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):